Pliant Therapeutics (PLRX) EBIT (2020 - 2025)
Historic EBIT for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$28.3 million.
- Pliant Therapeutics' EBIT rose 5441.51% to -$28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.1 million, marking a year-over-year increase of 1619.49%. This contributed to the annual value of -$228.4 million for FY2024, which is 2401.37% down from last year.
- Per Pliant Therapeutics' latest filing, its EBIT stood at -$28.3 million for Q3 2025, which was up 5441.51% from -$45.6 million recorded in Q2 2025.
- Over the past 5 years, Pliant Therapeutics' EBIT peaked at -$22.9 million during Q2 2021, and registered a low of -$62.0 million during Q3 2024.
- In the last 5 years, Pliant Therapeutics' EBIT had a median value of -$42.1 million in 2023 and averaged -$40.5 million.
- Per our database at Business Quant, Pliant Therapeutics' EBIT plummeted by 30820.31% in 2021 and then surged by 5441.51% in 2025.
- Pliant Therapeutics' EBIT (Quarter) stood at -$24.6 million in 2021, then crashed by 52.04% to -$37.4 million in 2022, then dropped by 25.77% to -$47.0 million in 2023, then decreased by 13.36% to -$53.3 million in 2024, then soared by 46.98% to -$28.3 million in 2025.
- Its last three reported values are -$28.3 million in Q3 2025, -$45.6 million for Q2 2025, and -$58.9 million during Q1 2025.